- Securities Registration: Employee Benefit Plan (S-8)
26 Giugno 2009 - 8:27PM
Edgar (US Regulatory)
As
filed with the Securities and Exchange Commission on June 26, 2009
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
MIDDLEBROOK PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50414
|
|
52-2208264
|
|
|
|
|
|
(State or Other Jurisdiction of
|
|
(Commission File Number)
|
|
(IRS Employer
|
Incorporation)
|
|
|
|
Identification No.)
|
7 Village Circle, Suite 100, Westlake, Texas 76262
(Address of Principal Executive Offices) (Zip Code)
Amended and Restated MiddleBrook Pharmaceuticals, Inc. Stock Incentive Plan
(Full title of the plan)
Brad Cole, Esq.
Senior Vice President, General Counsel and Secretary
MiddleBrook Pharmaceuticals, Inc.
7 Village Circle, Suite 100
Westlake, Texas 76262
(817) 837-1200
(Name and address of agent for service)
(Telephone number, including area code, of agent for service)
Copies To:
Frederick W. Kanner, Esq.
Dewey & LeBoeuf LLP
1301 Avenue of the Americas
New York, New York 10019
(212) 259-8000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated
filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
(Check one):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Large accelerated filer
o
|
|
Accelerated filer
þ
|
|
Non-accelerated filer
o
|
|
Smaller reporting company
o
|
|
|
|
|
(Do not check if a smaller reporting company)
|
|
|
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposed
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum
|
|
|
Proposed Maximum
|
|
|
|
|
|
Title of Securities to
|
|
|
Amount to be
|
|
|
Offering Price Per
|
|
|
Aggregate Offering
|
|
|
Amount of
|
|
|
be Registered
|
|
|
Registered(1)
|
|
|
Share(2)
|
|
|
Price(2)
|
|
|
Registration Fee
|
|
|
Common Stock, $0.01 par
value per share, reserved
for issuance pursuant to
the registrants Amended
and Restated Stock
Incentive Plan
|
|
|
3,500,000 shares
|
|
|
|
$1.56
|
|
|
|
$
|
5,460,000
|
|
|
|
$
|
304.67
|
|
|
|
|
|
|
(1)
|
|
In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement
shall be deemed to cover any additional securities that may from time to time be offered or issued to
prevent dilution resulting from stock splits, stock dividends or similar transactions.
|
|
(2)
|
|
Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and
457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low
prices of the Registrants Common Stock as reported on the NASDAQ Global Market on June 23, 2009.
|
EXPLANATORY STATEMENT
This Form S-8 Registration Statement is being filed with the Securities and Exchange
Commission (the Commission) by MiddleBrook Pharmaceuticals, Inc., a Delaware corporation (the
Company), in order to register 3,500,000 shares of the Companys common stock, par value $0.01
per share (the Common Stock), issuable upon exercise of options granted or to be granted under
the MiddleBrook Pharmaceuticals, Inc. Stock Incentive Plan (the Plan). On October 15, 2003, the
Company filed with the Commission a Registration Statement on Form S-8 (Registration
No. 333-109728) registering up to 4,567,679 shares of Common Stock issuable under the Plan (the
Initial Registration Statement). On August 6, 2004, the Company filed with the Commission a
Registration Statement on Form S-8 (Registration No. 333-118003) registering up to an additional
1,250,000 shares of Common Stock issuable under the Plan; on June 9, 2006 the Company filed with
the Commission a Registration Statement on Form S-8 (Registration No. 333-134913) registering up to
an additional 1,500,000 shares of Common Stock issuable under the Plan; and on February 11, 2009,
the Company filed with the Commission a Registration Statement on Form S-8 (Registration
No. 333-157261) registering up to an additional 8,500,000 shares of Common Stock issuable under the
Plan (such registration statements, together with the Initial Registration Statement, being
hereinafter referred to as the Prior Registration Statements). With the addition of 3,500,000
shares registered pursuant to this Registration Statement for issuance under the Plan, the total
number of shares now registered for issuance pursuant to the Plan is 19,317,679. Pursuant to
General Instruction E of Form S-8, the Company hereby incorporates by reference in this
Registration Statement all contents of the Prior Registration Statements, including the exhibits
thereto.
Part I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The information specified in Item 1 and Item 2 of Part I of this Registration
Statement on Form S-8 (the Registration Statement) is omitted from this filing in accordance with
the provisions of Rule 428 under the Securities Act of 1933, as amended. The documents containing
the information specified in Part I will be delivered to the participants in the plan covered by
this Registration Statement as required by Rule 428.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents filed with the Commission are hereby incorporated by
reference:
|
|
|
Our Annual Report on Form 10-K for the year ended December 31, 2008, filed on March 13, 2009, including
information incorporated by reference from our Definitive Proxy Statement on Schedule 14A for our annual
meeting of stockholders filed on April 30, 2009.
|
|
|
|
|
Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 filed with the Commission on May
11, 2009.
|
|
|
|
|
Our Current Reports on Form 8-K filed with the Commission on March 5, 2009, April 24, 2009 and May 7, 2009.
|
|
|
|
|
The description of our common stock which is contained in the Companys registration statement on Form S-1
(File No. 333-107599), as amended.
|
All other documents subsequently filed by the Registrant pursuant to Sections 13(a),
13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which
indicates that all securities offered hereunder have been sold or which deregisters all such
securities then remaining unsold shall be deemed to be incorporated by reference in this
Registration Statement and be a part hereof from the date of filing of such documents.
Any statement contained herein or in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or superseded for purposes of this
Registration Statement to the extent that a statement contained herein or in any other subsequently
filed document which also is or is deemed to be incorporated by reference herein modifies or
supersedes such earlier statement. Any statement so modified or superseded shall not be deemed,
except as so modified or superseded, to constitute a part of this Registration Statement.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 6. Indemnification of Directors and Officers.
Section 145 of the Delaware General Corporation Law provides that a Delaware
corporation may indemnify any person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative (other than an action by or in the right of the corporation) by
reason of the fact that the person is or was a director, officer, employee or agent of the
corporation, or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation or enterprise. The indemnity may include expenses
(including attorneys fees), judgments, fines and amounts paid in settlement actually and
reasonably incurred by the person in connection with the action, suit, or proceeding, provided the
person acted in good faith and in a manner he reasonably believed to be in or not opposed to the
corporations best interests and, with respect to any criminal action or proceeding, had no
reasonable cause to believe that his conduct was unlawful. A similar standard of care is applicable
in the case of actions by or in the right of the corporation, except that no indemnification may be
made in respect of any claim, issue or matter as to which such person will have been adjudged to be
liable to the corporation unless and only to the extent that the Delaware Court of Chancery or the
court in which such action was brought determines that, despite the adjudication of liability but
in view of all of the circumstances of the case, the person is fairly and reasonably entitled to
indemnity for expenses that the Delaware Court of Chancery or other court shall deem proper.
Our certificate of incorporation and bylaws provide that we will indemnify and
advance expenses to our directors, officers and employees to the fullest extent permitted by
Delaware law in connection with any threatened, pending or completed action, suit or proceeding to
which such person was or is a party or is threatened to be made a party by reason of the fact that
he or she is or was our director, officer or employee, or is or was serving at our request as a
director, officer, employee or agent of another corporation or enterprise. We have entered into
indemnification agreements with each of our directors and executive officers that provide them with
rights to indemnification and expense advancement to the fullest extent permitted under the
Delaware General Corporation Law.
We have purchased directors and officers liability insurance to insure our
directors and officers against liability for actions or omissions occurring in their capacity as a
director or officer, subject to certain exclusions and limitations.
Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
The following documents are filed as Exhibits hereto:
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
4.1
|
|
Specimen common stock certificate, filed as an exhibit to the Companys registration statement on
Form S-1 (File No. 333-107599)
|
|
|
|
4.2
|
|
Amended and Restated MiddleBrook Pharmaceuticals, Inc. Stock Incentive Plan
|
|
|
|
5.1
|
|
Opinion and Consent of Dewey & LeBoeuf LLP with respect to the legality of the securities being registered
|
|
|
|
23.1
|
|
Consent of Dewey &LeBoeuf LLP (contained in their opinion filed herewith as Exhibit 5.1)
|
|
|
|
23.2
|
|
Consent of PricewaterhouseCoopers LLP
|
|
|
|
24.1
|
|
Power of Attorney of directors and certain officers of the Company (included in Signature Page)
|
Item 9. Undertakings.
The undersigned registrant hereby undertakes:
|
(1)
|
|
To file, during any period in which offers or sales are being made, a post-effective amendment to
this registration statement:
|
|
(i)
|
|
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
|
|
|
(ii)
|
|
To reflect in the prospectus any facts or events arising after the effective date of
the registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the
information set forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value
of securities offered would not exceed that which was registered) and any deviation
from the low or high end of the estimated maximum offering range may be reflected in
the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the
aggregate, the changes in volume and price represent no more than a 20 percent
change in the maximum aggregate offering price set forth in the Calculation of
Registration Fee table in the effective registration statement;
|
|
|
(iii)
|
|
To include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to such
information in the registration statement;
|
|
|
|
Provided, however
, that paragraphs (i) and (ii) above do not apply if the
information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the Commission by
the registrant pursuant to section 13 or section 15(d) of the Securities
Exchange Act of 1934 that are incorporated by reference in the registration
statement.
|
|
|
(2)
|
|
That, for the purpose of determining any liability under the
Securities Act of 1933, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
|
|
|
(3)
|
|
To remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the
termination of the offering.
|
The undersigned registrant hereby undertakes that, for purposes of determining any liability under
the Securities Act of 1933, each filing of the registrants annual report pursuant to section 13(a)
or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an
employee benefit plans annual report pursuant to section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in the registration statement shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to directors, officers and controlling persons of the registrant pursuant to the
foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in
the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such
issue.
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Westlake, State of Texas, on June 23, 2009.
|
|
|
|
|
|
MIDDLEBROOK PHARMACEUTICALS, INC.
|
|
By:
|
/s/ John Thievon
|
|
|
|
John Thievon
|
|
|
|
President and Chief Executive Officer
|
|
|
Pursuant to the requirements of the Securities Act of 1933 this registration
statement has been signed by the following persons in the capacities and on the dates stated. Each
person whose signature appears below hereby constitutes and appoints John Thievon, Dave Becker,
Brad Cole, or any of them, as such persons true and lawful attorney-in-fact and agent with full
power and substitution for such person and in such persons name, place and stead, in any and all
capacities, to sign and to file with the Securities and Exchange Commission, any and all amendments
and post-effective amendments to this Registration Statement, with exhibits thereto and other
documents in connection therewith, including any registration statements or amendments thereto
filed pursuant to Rule 462(b) under the Securities Act of 1933, granting unto said attorney-in-fact
and agent full power and authority to do and perform each and every act and thing requisite and
necessary to be done in and about the premises, as fully to all intents and purposes as such person
might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and
agent or any substitute therefor, may lawfully do or cause to be done by virtue thereof.
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ John Thievon
John Thievon
|
|
President, Chief Executive Officer and
Director
(Principal Executive Officer)
|
|
June 23, 2009
|
/s/ David Becker
David Becker
|
|
Executive Vice President, Chief Financial
Officer
(Principal Financial and
Accounting Officer)
|
|
June 23, 2009
|
/s/ R. Gordon Douglas
R. Gordon Douglas, M.D.
|
|
Chairman of the Board of Directors
|
|
June 23, 2009
|
/s/ Lord James Blyth
Lord James Blyth
|
|
Vice Chairman of the Board of Directors
|
|
June 23, 2009
|
/s/ James H. Cavanaugh
James H. Cavanaugh, Ph.D.
|
|
Director
|
|
June 23, 2009
|
/s/ Richard W. Dugan
Richard W. Dugan
|
|
Director
|
|
June 23, 2009
|
/s/ William C. Pate
William C. Pate
|
|
Director
|
|
June 23, 2009
|
/s/ Mark Sotir
Mark Sotir
|
|
Director
|
|
June 23, 2009
|
/s/ Martin A. Vogelbaum
Martin A. Vogelbaum
|
|
Director
|
|
June 23, 2009
|
/s/ Harold R. Werner
Harold R. Werner
|
|
Director
|
|
June 23, 2009
|
Grafico Azioni Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Storico
Da Giu 2023 a Giu 2024